Weekly Reads: Lab-Grown Sperm, Stem Cell Pills, Intranasal EVs, EMF Cell Paper Doubts, Makary Toast?

Key Takeaways

• Paterna claims first lab‑grown human sperm from stem cells
• EMF gene‑control paper faces image‑flipping criticism on PubPeer
• Stem‑cell supplement scams mislead consumers, lacking scientific basis
• Intranasal EV therapy shows brain anti‑inflammatory effects in mice
• Marty Makary's FDA role under political pressure, possible dismissal

Pulse Analysis

The promise of in vitro gametogenesis (IVG) has leapt forward as Paterna Biosciences announced the creation of functional human sperm from stem cells. By bypassing the need for donor sperm, the technology could lower costs and expand options for men with azoospermia, while also providing a scalable platform for embryology research. Industry observers caution that translating laboratory success into clinical practice will require extensive safety testing, regulatory approval, and ethical frameworks before IVF clinics can adopt stem‑cell‑derived gametes.

Scientific credibility is being tested on another front. A high‑profile Cell paper from South Korea claimed that electromagnetic fields could toggle gene expression, a claim now marred by flipped microscopy images identified on PubPeer. The episode highlights the broader challenge of reproducibility in cutting‑edge biotech, especially as hype fuels consumer products like unproven stem‑cell pills and intranasal extracellular‑vesicle (EV) therapies. While early animal data suggest EVs can dampen neuroinflammation, the rush of clinics offering such treatments without rigorous trials raises safety and regulatory red flags.

The biotech landscape is also shaped by political currents. Reports that President Trump may fire FDA Commissioner Marty Makary reflect tension between regulatory independence and executive priorities, particularly around issues such as flavored vaping products and the FDA’s Center for Biologics Evaluation and Research (CBER). A leadership change could alter the agency’s stance on emerging therapies, from gene‑editing to stem‑cell‑derived gametes, influencing investment, approval timelines, and public trust. Stakeholders therefore watch both scientific validation and policy shifts closely, recognizing that progress in the lab must be matched by transparent oversight.